Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia.

Ma J, Ning YN, Xu M, Hou Y, Wang N, Hou XY, Yu YY, Li H, He WD, Shao LL, Zhou H, Min YN, Liu XG, Shi Y, Qin P, Guo CS, Hou M, Peng J.

Blood. 2013 Sep 19;122(12):2074-82. doi: 10.1182/blood-2013-03-491555. Epub 2013 Aug 7.

2.

Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura.

Zhang XL, Peng J, Sun JZ, Guo CS, Yu Y, Wang ZG, Chu XX, Hou M.

J Thromb Haemost. 2008 Jan;6(1):158-65. Epub 2007 Oct 15.

3.

Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients.

Ma L, Zhou Z, Zhang D, Yang S, Wang J, Xue F, Yang Y, Yang R.

Thromb Haemost. 2012 May;107(5):937-50. doi: 10.1160/TH11-08-0596. Epub 2012 Mar 8.

PMID:
22398715
4.

The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia.

Zhang D, Li H, Ma L, Zhang X, Xue F, Zhou Z, Chi Y, Liu X, Huang Y, Yang Y, Yang R.

Autoimmunity. 2014 Dec;47(8):519-29. doi: 10.3109/08916934.2014.938320. Epub 2014 Jul 14.

PMID:
25019270
5.

Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia.

Xu SQ, Wang CY, Zhu XJ, Dong XY, Shi Y, Peng J, Qin P, Sun JZ, Guo C, Ni H, Hou M.

Ann Hematol. 2012 Oct;91(10):1623-31. doi: 10.1007/s00277-012-1451-0. Epub 2012 Apr 13.

PMID:
22526360
6.

Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia.

Catani L, Sollazzo D, Trabanelli S, Curti A, Evangelisti C, Polverelli N, Palandri F, Baccarani M, Vianelli N, Lemoli RM.

Ann Hematol. 2013 Jan;92(1):67-78. doi: 10.1007/s00277-012-1556-5. Epub 2012 Aug 31.

PMID:
22936460
7.

Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression.

Zhang JM, Feng FE, Wang QM, Zhu XL, Fu HX, Xu LP, Liu KY, Huang XJ, Zhang XH.

Stem Cells Transl Med. 2016 Dec;5(12):1631-1643. Epub 2016 Jul 28.

8.

Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells.

Yañez R, Oviedo A, Aldea M, Bueren JA, Lamana ML.

Exp Cell Res. 2010 Nov 15;316(19):3109-23. doi: 10.1016/j.yexcr.2010.08.008. Epub 2010 Sep 8.

PMID:
20804749
9.

Tolerogenic dendritic cells as a target for the therapy of immune thrombocytopenia.

Fu J, Zhang A, Ju X.

Clin Appl Thromb Hemost. 2012 Sep;18(5):469-75. doi: 10.1177/1076029612438612. Epub 2012 Mar 2. Review.

PMID:
22387587
10.

Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes.

Catani L, Fagioli ME, Tazzari PL, Ricci F, Curti A, Rovito M, Preda P, Chirumbolo G, Amabile M, Lemoli RM, Tura S, Conte R, Baccarani M, Vianelli N.

Exp Hematol. 2006 Jul;34(7):879-87.

PMID:
16797415
11.
12.

Immunomodulatory function of regulatory dendritic cells induced by mesenchymal stem cells.

Zhao ZG, Xu W, Sun L, You Y, Li F, Li QB, Zou P.

Immunol Invest. 2012;41(2):183-98. doi: 10.3109/08820139.2011.607877. Epub 2011 Sep 21.

PMID:
21936678
13.

The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia.

Zhao ZG, Xu W, Sun L, Li WM, Li QB, Zou P.

Eur J Cancer. 2012 Aug;48(12):1884-95. doi: 10.1016/j.ejca.2011.11.003. Epub 2011 Nov 28.

PMID:
22129888
14.

Plasmacytoid dendritic cells, interferon signaling, and FcγR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia.

Sehgal K, Guo X, Koduru S, Shah A, Lin A, Yan X, Dhodapkar KM.

Sci Transl Med. 2013 Jul 10;5(193):193ra89. doi: 10.1126/scitranslmed.3006277.

15.
16.

Differential expression of T-cell genes in blood and bone marrow between ITP patients and controls.

Jernås M, Nookaew I, Wadenvik H, Olsson B.

Thromb Haemost. 2013 Jan;109(1):112-7. doi: 10.1160/TH12-07-0468. Epub 2012 Nov 8.

PMID:
23138397
17.

Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura.

Pérez-Simón JA, Tabera S, Sarasquete ME, Díez-Campelo M, Canchado J, Sánchez-Abarca LI, Blanco B, Alberca I, Herrero-Sánchez C, Cañizo C, San Miguel JF.

Cytotherapy. 2009;11(6):698-705. doi: 10.3109/14653240903051558.

PMID:
19878056
18.

Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells.

Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M.

Blood. 2006 May 1;107(9):3632-8. Epub 2006 Jan 5.

19.

Mesenchymal stem cells from periapical lesions modulate differentiation and functional properties of monocyte-derived dendritic cells.

Dokić J, Tomić S, Marković M, Milosavljević P, Colić M.

Eur J Immunol. 2013 Jul;43(7):1862-72. doi: 10.1002/eji.201243010. Epub 2013 May 28.

20.

Induction of tolerogenic dendritic cells by vitamin D receptor agonists.

Adorini L, Penna G.

Handb Exp Pharmacol. 2009;(188):251-73. doi: 10.1007/978-3-540-71029-5_12. Review.

PMID:
19031030

Supplemental Content

Support Center